CTOs on the Move

Reckitt Benckiser

www.rb.com

 
We protect, heal and nurture in the relentless pursuit of a cleaner, healthier world. Our products reach millions of people every day, as we fight to improve global access to the highest quality hygiene, wellness and nourishment. We`re a growing community of 40,000+ diverse, talented entrepreneurs, and the driving force behind some of the world`s most loved and trusted brands. Our portfolio includes household names such as Enfamil, Nutramigen, Nurofen, Strepsils, Gaviscon, Mucinex, Durex, Lysol, Dettol, Harpic, Cillit Bang, Finish and Vanish. Hygiene, Health and Nutrition are the focus areas of our business, and the categories under which our brands ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.rb.com
  • 399 Interpace Parkway P.O. Box 225
    Parsippany, NJ USA 07054
  • Phone: 973.404.2600

Executives

Name Title Contact Details
Rama Donepudi
 Chief Information Officer (CIO), Global Nutrition at Reckitt Profile
Filippo Catalano
 Chief Information and Digitisation Officer Profile
Magdalena Skorupa
 Director of Cyber Risk and Compliance Profile

Similar Companies

Blood Systems

Blood Systems is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hunstman Expandable Polymers Co.

Hunstman Expandable Polymers Co. is a High Point, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Life Skills U

Life Skills U is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cooperative Home Care

Cooperative Home Care is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bionor Pharma

Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.